Ignite Creation Date:
2025-12-25 @ 4:18 AM
Ignite Modification Date:
2025-12-26 @ 3:19 AM
Study NCT ID:
NCT06373120
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-05-06
First Post:
2024-03-11
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Interventional Ventricular Assist System for PCI in CHIP Patients
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR'], 'maskingDescription': 'A blinded and independent clinical event adjudication committee will adjudicate all primary and secondary outcomes'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Prospective, 1:1 randomized, controlled, multicenter trial to assess effectiveness and safety of CorVad compared to VA-ECMO in complicated and high-risk patient with indications for PCI'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 262}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2024-03-04', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-05', 'completionDateStruct': {'date': '2026-02-13', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-05-01', 'studyFirstSubmitDate': '2024-03-11', 'studyFirstSubmitQcDate': '2024-04-15', 'lastUpdatePostDateStruct': {'date': '2025-05-06', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2024-04-18', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-02-13', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Device-related composite endpoint (DoCE)', 'timeFrame': '1, 3, 12, 24, 36, and 60 months', 'description': 'Device-related composite endpoint (DoCE), defined as: cardiac death, target-vessel myocardial infarction (TV-MI), clinically and physiologically driven target lesion revascularization (CPI-TLR)'}, {'measure': 'Patient-related composite endpoint (PoCE)', 'timeFrame': '1, 3, 12, 24, 36, and 60 months', 'description': 'Patient-related composite endpoint (PoCE), defined as: all-cause death, any stroke, any myocardial infarction, and any revascularization'}, {'measure': 'Net adverse clinical events', 'timeFrame': '1, 3, 12, 24, 36, and 60 months', 'description': 'Net adverse clinical events, defined as: PoCE + MCS-ARC defined type 3, 4, 5 bleeding'}, {'measure': 'Cardiac death', 'timeFrame': '1, 3, 12, 24, 36, and 60 months'}, {'measure': 'Ischemic stroke', 'timeFrame': '1, 3, 12, 24, 36, and 60 months'}, {'measure': 'Hemorrhagic stroke', 'timeFrame': '1, 3, 12, 24, 36, and 60 months'}, {'measure': 'Transient ischemic attack', 'timeFrame': '1, 3, 12, 24, 36, and 60 months'}, {'measure': 'Target vessel myocardial infarction', 'timeFrame': '1, 3, 12, 24, 36, and 60 months'}, {'measure': 'Target lesion revascularization', 'timeFrame': '1, 3, 12, 24, 36, and 60 months'}, {'measure': 'Target vessel revascularization', 'timeFrame': '1, 3, 12, 24, 36, and 60 months'}, {'measure': 'Clinically and physiologically driven target lesion revascularization (CPI-TLR)', 'timeFrame': '1, 3, 12, 24, 36, and 60 months'}, {'measure': 'Rehospitalization', 'timeFrame': '1, 3, 12, 24, 36, and 60 months'}, {'measure': 'MCS-ARC type 2 bleeding', 'timeFrame': '1 month'}, {'measure': 'Puncture complications', 'timeFrame': '1 month', 'description': 'Puncture complications: Vascular complications or percutaneous vascular suture failure'}, {'measure': 'Aortic valve injury', 'timeFrame': '1 month', 'description': 'Aortic valve injury is defined as the occurrence of moderate and severe aortic valve regurgitation in patients with no pre-operative aortic valve regurgitation or mild regurgitation'}, {'measure': 'Active Infection', 'timeFrame': '1 month', 'description': 'Active infection refers to an infection accompanied by clinical evidence, including pain, fever, or imaging findings consistent with infection, and requires the use of antimicrobial drugs for treatment. The definition of infection requires positive culture results from the site or organ of infection, unless there is strong clinical evidence indicating the presence of infection and the need for treatment.'}, {'measure': 'ECMO/Corvad setup time', 'timeFrame': 'assessed at index PCI procedure', 'description': 'Setup time is defined as the time from starting vessel puncture to the time providing cardiac support by the device'}, {'measure': 'Complete revascularization rate', 'timeFrame': '1 month', 'description': 'Complete revascularization is defined as the residual SYNTAX score ≤ 8 points'}, {'measure': 'Change in left ventricular ejection fraction (LVEF) from baseline', 'timeFrame': '1, 12, 24, 36, and 60 months'}, {'measure': 'Change in New York Heart Association (NYHA) classification from baseline', 'timeFrame': '1, 12, 24, 36, and 60 months'}, {'measure': 'Change in Seattle Angina Questionnaire (SAQ) score from baseline', 'timeFrame': '1, 12, 36, and 60 months', 'description': 'The SAQ is a 19-item self-administered disease-specific patient-reported outcome measure with 5 domains: physical limitation, angina stability, angina frequency, treatment satisfaction, and disease perception and/or quality of life. It was to identify a conceptual framework with which to elicit the important manifestations of coronary disease from the patient perspective. All SAQ domain scores and the summary score range from 0 to 100 points, with higher scores indicating less angina, fewer functional limitations, and better quality of life.'}, {'measure': 'Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score from baseline', 'timeFrame': '1, 12, 36, and 60 months', 'description': 'The KCCQ is a self-administered, 23-item questionnaire that quantifies physical limitations, symptoms, self-efficacy, social interference and quality of life. KCCQ scores range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations.'}, {'measure': 'Change in 5-level EQ-5D version (EQ-5D-5L) standardized health status scale score from baseline', 'timeFrame': '1, 12, 36, and 60 months', 'description': 'The EQ-5D is a standardized instrument for use as a measure of health outcome which can be divided into two parts: the EQ-5D health description system and the EQ-vas. EQ-5D-5L questionnaire is a five-item scale assessing five separate dimensions of health: (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has to be answered on a five-level scale (no problems, slight problems, moderate problems, severe problems and extreme problems). The EQ-VAS is a 20 cm long vertical visual scale. A score of 100 at the top represents "best perceived health status" and a score of 0 at the bottom represents "worst perceived health status".'}, {'measure': 'Change in creatinine clearance rate from baseline', 'timeFrame': '1 month'}, {'measure': 'Stent thrombosis', 'timeFrame': '1, 3, 12, 24, 36, and 60 months'}], 'primaryOutcomes': [{'measure': 'Major adverse event', 'timeFrame': '1 month', 'description': 'Major adverse event is a composite endpoint, defined as all-cause death, stroke, myocardial infarction, revascularization, cardiovascular hospitalization, MCS-ARC defined bleeding types 3, 4, or 5, acute kidney injury, serious device-related adverse events, cardiopulmonary resuscitation'}], 'secondaryOutcomes': [{'measure': 'All-cause death', 'timeFrame': '1, 3, 12, 24, 36, and 60 months'}, {'measure': 'Stroke', 'timeFrame': '1, 3, 12, 24, 36, and 60 months'}, {'measure': 'Myocardial infarction', 'timeFrame': '1, 3, 12, 24, 36, and 60 months'}, {'measure': 'Revascularization', 'timeFrame': '1, 3, 12, 24, 36, and 60 months'}, {'measure': 'Cardiovascular hospitalization', 'timeFrame': '1, 3, 12, 24, 36, and 60 months', 'description': 'Rehospitalization due to cardiovascular reasons'}, {'measure': 'MCS-ARC defined type 3, 4, 5 bleeding', 'timeFrame': '1 month', 'description': 'Bleeding is defined by the "Updated definitions of adverse events for trials and registries of mechanical circulatory support: A consensus statement of the mechanical circulatory support academic research consortium" (MRC-ARC)'}, {'measure': 'Acute kidney injury', 'timeFrame': '1 month'}, {'measure': 'Serious device-related adverse events', 'timeFrame': '1 month', 'description': 'Including but not limited to cardiac structural impairment, severe limb ischemia (pale, pulseless, and necrotic), infection, aortic and aortic valve impairment, hemolysis, peri-procedural complications that cause death, permanent/severe disability to the subject, or significantly prolonged hospital stay or need for surgical intervention'}, {'measure': 'Cardiopulmonary resuscitation', 'timeFrame': '1 month'}, {'measure': 'Hospitalization time', 'timeFrame': '1 month'}, {'measure': 'Intensive care unit (ICU/CCU) stay time', 'timeFrame': '1 month'}, {'measure': 'ECMO/Corvad utilization time', 'timeFrame': '1 month'}, {'measure': 'Hemodynamic disorder', 'timeFrame': '1 month', 'description': 'Hemodynamic disorder is defined as average arterial pressure (MAP) below 60 mmHg for more than 10 minutes with the requirement of additional vasoactive medications'}, {'measure': 'Transfusion rate', 'timeFrame': '1 month', 'description': 'Transfusion rate is defined as patients who had transfusion / all enrolled patients.'}, {'measure': 'Units of transfusion', 'timeFrame': '1 month'}, {'measure': 'Major adverse event', 'timeFrame': '3, 12, 24, 36, and 60 months', 'description': 'Major adverse event is a composite endpoint, defined as all-cause death, stroke, myocardial infarction, revascularization, cardiovascular hospitalization, MCS-ARC defined bleeding types 3, 4, or 5, acute kidney injury, serious device-related adverse events, cardiopulmonary resuscitation'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Microaxial flow pump', 'ECMO', 'Percutaneous Coronary Intervention', 'left ventricular assist devices'], 'conditions': ['High-Risk Percutaneous Coronary Intervention (High-risk PCI)', 'Left Ventricular Assist Devices']}, 'descriptionModule': {'briefSummary': 'In patients with complex coronary artery disease (CAD), determining the optimal revascularization strategy (percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) remains a challenge. These high-risk patients pose an extreme surgical risk. However, with the development of new interventional techniques and materials, PCI is a good alternative to CABG and is referred to as complex high-risk indicated PCI (CHIP).\n\nDuring CHIP, hemodynamics can deteriorate because of temporary complete coronary occlusion or profound myocardial ischemia. This could result in loss of cardiac output and hemodynamics collapse. Mechanical support during CHIP facilitates native cardiac function by achieving a stable hemodynamic state to withstand repetitive derangements such as ischemia caused by prolonged and repeated balloon inflations, and resume original cardiac function immediately postprocedure or shortly thereafter.\n\nThere are several mechanical circulatory support (MCS) systems available, i.e., intra-aortic balloon counterpulsation (IABP), Impella, TandemHeart, and veno-arterial extracorporeal membrane oxygenation (VA-ECMO). These MCS have been widely studied in patients with acute myocardial infarction (MI) complicated by cardiogenic shock and showed conflicting results. However, studies regarding the use of MCS in the setting of CHIP are much less abundant and no randomized study has compared Impella with VA-ECMO in CHIP patients.\n\nThe aim of the study is to evaluate the effectiveness of interventional ventricular assist system (CorVad) compared to the venoarterial extracorporeal membrane oxygenation (VA-ECMO) system in providing circulatory support for complicated and high-risk patient with indications for PCI.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '90 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. 18 Years to 90 Years\n2. The Heart Team determined that the patients required coronary artery revascularization, but there is a high risk of CABG or the patients refuses CABG. After evaluation by the Heart Team, it was concluded that the patients can benefit from revascularization by undergoing high risk PCI\n3. The subject is diagnosed with acute or chronic coronary syndrome, and\n\n 1. LVEF≤ 35% or\n 2. LVEF ≤ 40% and NYHA Classification is III or IV\n4. Patients who are able to give informed consent and complete the follow-up\n\nImage inclusion criteria\n\n1. At least two vessel chronic total occlusions (CTOs) (diameter of occluded artery ≥ 2.5mm)\n2. Unprotected left main coronary artery disease, and meeting one or more complex PCI maneuver criteria\n3. Three-vessel disease and meeting two or more complex PCI criteria\n\nComplex PCI maneuvers are defined as:\n\n1. Bifurcation require the treatment of both branches (including stents or PTCA)\n2. Calcification require Excimer laser coronary atherectomy, intravascular lithotripsy, or rotational atherectomy\n3. Severe tortuosity\n4. Target lesion is CTO (diameter of occluded artery ≥ 2.5mm and J-CTO score ≥ 2 points)\n\nExclusion Criteria\n\n1. Had mechanical circulatory support treatment (such as IABP, ECMO, pVAD) before randomization\n2. Acute myocardial infarction or with thrombolytic treatment within 7 days\n3. Cardiopulmonary resuscitation within 24 hours\n4. Cardiogenic shock (systolic blood pressure \\< 90 mmHg for more than 30 minutes or requiring vasoactive drugs to maintain systolic blood pressure above 90 mmHg) or hemodynamically unstable\n5. pVAD and ECMO cannot be inserted or contraindicated (including but not limited to left ventricular mural thrombus, artificial aortic valve or cardiac contraction device, moderate to severe aortic stenosis, moderate to severe aortic valve insufficiency, peripheral stents, tortuosity, dissection and other severe vascular diseases obstructing the insertion of the study device, aortic dissection, aneurysm or severe abnormalities of the ascending aorta and/or aortic arch, red blood cell fragility or blood disorders, hypertrophic obstructive cardiomyopathy)\n6. Abnormal coagulation function (routine blood test indicates platelet count less than 50×109/L, or more than 700×109/L)\n7. Active visceral bleeding occurred within 1 month\n8. Ischemic or hemorrhagic stroke occurred within 1 month\n9. Known contraindication to antiplatelet and anticoagulant medications\n10. Known contraindication to medications such as Heparin or contrast.\n11. Need for dialysis treatment\n12. Active infection\n13. Expected life span of less than one year\n14. Patient is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential according to local practice)\n15. Currently participating in another trial and not yet at its primary endpoint\n16. Severe pulmonary arterial hypertension\n17. Severe right heart failure or severe tricuspid regurgitation\n18. Unforeseen circumstances that the researcher has deemed to be inappropriate'}, 'identificationModule': {'nctId': 'NCT06373120', 'acronym': 'REC-CHIPMCS', 'briefTitle': 'Interventional Ventricular Assist System for PCI in CHIP Patients', 'organization': {'class': 'INDUSTRY', 'fullName': 'Shenzhen Core Medical Technology CO.,LTD.'}, 'officialTitle': 'Interventional Ventricular Assist System for PCI in Complicated and High-risk Patient: a Prospective, Multicenter, Randomized Trial', 'orgStudyIdInfo': {'id': 'QX20231057-X-1'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Microaxial flow pump', 'description': 'The microaxial flow pump (The CorVad percutaneous ventricular assist system) will offer intraoperative hemodynamic support during high-risk PCI procedures.', 'interventionNames': ['Device: Microaxial flow pump']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'VA-ECMO', 'description': 'The VA-ECMO offers intraoperative hemodynamic support during high-risk PCI procedures.', 'interventionNames': ['Device: VA-ECMO']}], 'interventions': [{'name': 'Microaxial flow pump', 'type': 'DEVICE', 'description': 'The microaxial flow pump (The CorVad percutaneous ventricular assist system device) is a microaxial rotary blood pump that expels blood from the left ventricle into the ascending aorta, thus unloading the left ventricle. The CorVad system device can be introduced through a femoral percutaneous approach (14Fr) and can deliver an output of up to 4-6 L/min.', 'armGroupLabels': ['Microaxial flow pump']}, {'name': 'VA-ECMO', 'type': 'DEVICE', 'description': 'Veno-arterial extracorporeal Membrane Oxygenation (VA-ECMO) is a device originally created to replace heart and lung function. Venous deoxygenated blood is mechanically suctioned from a large central vein through a venous cannula by a centrifugal pump. It is then oxygenated, warmed, and restored into systemic circulation through an arterial cannula.', 'armGroupLabels': ['VA-ECMO']}]}, 'contactsLocationsModule': {'locations': [{'zip': '710032', 'city': "Xi'an", 'state': 'Shannxi', 'country': 'China', 'facility': 'Ling Tao', 'geoPoint': {'lat': 34.25833, 'lon': 108.92861}}], 'overallOfficials': [{'name': 'Ling Tao, M.D., Ph.D.', 'role': 'STUDY_CHAIR', 'affiliation': 'Xijing Hospital'}, {'name': 'Chao Gao, M.D., Ph.D.', 'role': 'STUDY_CHAIR', 'affiliation': 'Xijing Hospital'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Shenzhen Core Medical Technology CO.,LTD.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}